Author: Julie Kaloides

Dayton, OH May 5, 2016 – CSafe Global, a world leader in performance cold-chain solutions for the life sciences sector, announced it has appointed Sébastien Berrous as Director of Sales for France and Spain, where the company enjoys a rapidly expanding market presence.
As part of a vigorous expansion drive which is seeing CSafe Global open new operational service centres around the world to support the rapidly growing needs of life science customers, Sébastien Berrous will be responsible for the company’s overall business in France and Spain. “Sébastien brings a wealth of medical sales leadership experience to our European team and will be instrumental in helping many of the top biopharmaceutical companies in Europe solve their most pressing high risk cold chain challenges. His experience driving strategic market development excellence in senior roles at GE Healthcare and most recently at B. Braun, as France’s Managing Director of Inkospor branch, prepares Sebastien to best serve the market value priorities in France and Spain. We are very pleased to have Sebastien join the team and have every confidence in his market growth expertise as we continue to expand these important markets in Europe,” comments Nadine Siqueland, CSafe Vice President of Global Sales.
CSafe solutions are used for the protection of temperature-sensitive biopharmaceutical products and provide life science companies with the necessary margin of safety when it comes to protecting medicines during their long journey from producer to consumer. France is a major market for pharmaceuticals. It is Europe’s fourth largest producer, third largest importer, fourth largest exporter and second largest consumer. Spain is Europe’s fourth largest pharma employer and sixth in terms of both production and consumption. Taken together the two countries constitute Europe’s biggest concentration of pharma production.
Commenting on joining CSafe, Sebastien Berrous stated: “This is a very exciting time to be joining CSafe Global which stands out in the pharma-logistics sector as a dynamic, innovative and customer-centric company. I am looking forward to building on the successes already achieved and growing CSafe’s biopharmaceutical base in France and Spain.”

Columbus, OH May 4, 2016 – Quantum Health Inc., a leader in care coordination and consumer navigation, announces today the addition of Kelly Kaufman to their clinical team as Manager of Pharmacy Services. She will provide pharmaceutical expertise in support of Quantum Health’s internal clinical staff as well as Quantum Health’s members.
Kelly will be an integral part as Quantum Health continues to expand their pharmacy and medication expertise, along with strengthen their relationships with PBM vendor partners as the healthcare landscape continues to evolve.
“We’re thrilled Kelly has joined our team,” says Chief Medical Officer, Dr. Dana Andrews, MD. “Her extensive pharmaceutical knowledge and experience will be invaluable in our mission to provide our consumers and clients with an exceptional healthcare experience.”
Kaufman’s career spans more than 10 years in the pharmacy and pharmacy benefits industry. Most recently, she served as Clinical Pharmacy Liaison at Helios, a pharmacy benefits management company, where she implemented clinical programs to assist clients with managing claims and reducing costs.
Kaufman is an alumna of Ohio Northern University, where she earned a BS in pharmacy. She currently holds active pharmacy licenses in Ohio, Kentucky, and Pennsylvania.
About Quantum Health
Quantum Health is an award-winning care coordination and consumer navigation company serving the needs of self-insured public and private employers across the United States since 1999. With a background in consumer behavior and a deep understanding of how real people experience healthcare, Quantum Health has a proven history of improving the efficiency of clients’ benefits plans while maintaining industry-leading satisfaction rates and claims savings. Based in Columbus, Ohio, Quantum Health has been recognized on the Inc. 5000 as one of the fastest-growing privately held companies for the past seven consecutive years (2008-2015), listed as one of the 50 Fastest Growing Women Owned/Led Companies by the Women Presidents’ Organization and has been listed as both a FORTUNE Magazine Great Place to Work® and an Entrepreneur Magazine Great Place to Work®. Learn more at Quantum-Health.com, and connect with us on Twitter (@QuantumHealth1), and LinkedIn (Company: Quantum Health).

Austin, TX May 3, 2016 – HealthTronics Inc., a leading provider of mobile medical technologies, announced that AUA2016, the American Urological Association annual meeting to be held May 6-10 in San Diego, California, will include 11 presentations from world-wide experts to help urologists increase their knowledge of appropriate use and follow up for prostate and kidney cryoablation.
Cryoablation is a technology that uses small ice crystals to kill cancer cells with extreme cold. Endocare, Inc., a subsidiary of HealthTronics, Inc., manufactures the leading cryotherapy treatment devices for urologic applications. For more information on cryoablation, visit www.StopCancerCold.com.
“As cryotherapy plays an increasingly important role in urologic medicine, HealthTronics is committed to working with urology leaders to further groundbreaking research and the advancement of prostate and kidney cancer treatments,” said Russell Newman, HealthTronics’ president.
The AUA2016 cryotherapy presentations are:

• “Post-Salvage Therapy, Particularly with Nadir PSA<1, Delays the Time to Subsequent Androgen Deprivation Therapy.” Abstract number: MP14-05
• “Predictors of Local Disease Control After Salvage Whole Gland Prostate Cryoablation.” Abstract number: MP18-03
• “Whole Gland Salvage Cryoablation of Prostate: Long-Term Oncological Outcomes.” Abstract number: MP18-04
• “Evaluation of Urinary Function After Cryoablation of the Prostate.” Abstract number: MP18-12
• “Comparisons of Oncological and Functional Outcomes Among Radical Retropubic Prostatectomy, High Dose Rate Brachytherapy, Cryoablation and High-intensity Focused Ultrasound for Localized Prostate Cancer: A Prospective, Controlled, Nonrandomized Trial.” Abstract number: MP18-17
• “Comparison of Contrast-Enhanced Ultrasound Scan (CEUS) and MRI in the Follow-up of Cryoablation for Small Renal Tumors. Experience with 80 Cases.” Abstract number: MP19-05
• “Percentage of Renal Parenchymal Preservation and Renal Tumor Morphology are Determinants of Renal Functional Outcome Following Percutaneous Cryoablation.” Abstract number: S&T-02
• “Cryoablation versus Partial Nephrectomy for Clinical T1b Tumors: A Matched Group Analysis.” Abstract number: MP64-04
• “Comparison of Radiation Dosages Between CT-Guided and Ultrasound-Facilitated CT-Guided Percutaneous Cryoablation of Small Renal Cortical Neoplasms.” Abstract number: PD46-01
• “Evaluation of Skin-to-Tumor Distance as a Predictor of Tumor Recurrence Following Percutaneous Cryoablation of Renal Cortical Neoplasms.” Abstract number: PD46-03
• “Salvage Percutaneous Cryoablation for Locally Recurrent Renal Cell Carcinoma After Primary Cryoablation.” Abstract number: PD46-05

Additional information can be found at www.aua2016/abstracts.
 

Dayton, OH Apr 25, 2016 – In a continuing move to support their growing biopharmaceutical customers in the Northeast United States, CSafe Global announces that Tammy Orr has joined them as Director of Sales. Tammy joins CSafe from FedEx Custom Critical where her career spanned twenty-five years, during which she held senior positions in biopharmaceutical business development, key account sales management and operations. To further facilitate the business growth in the Northeast, CSafe announced the expansion of their Newark, New Jersey service center.
“We are pleased to have Tammy join our sales team,” says Nadine Siqueland, CSafe Vice President of Global Sales. “Her sound biopharmaceutical cool chain expertise is second to none with highly refined consultative skills which will enable CSafe to continue to deliver optimized customer partnership. Tammy will support our Northeast US biopharmaceutical customers with CSafe’s entire suite of active and passive temperature-management solutions.”
Tammy was the recipient of the coveted President’s Club Award on no less than four occasions and was a finalist for the 2015 North American Salesperson of the Year award. “My career to date has been positive and personally rewarding. I am now excited to be a part of this ever growing and successful company at such a dynamic time in pharmaceutical cool chain evolution when we can help optimize effective temperature controlled supply chain globally,” she states.
“This is the latest in series of strategic program investments being made by CSafe to maximize our capability to perform as the only global cool chain solution manufacturer that can provide both active and passive options to the life-sciences sector,” added Siqueland.

New York, NY: Altaris Capital Partners, LLC is pleased to announce the sale of M2S, Inc. to Medstreaming, LLC.
Founded in 1997 and headquartered in West Lebanon, NH, M2S provides patient data registry and advanced imaging services to healthcare providers, clinicians and clinical trial sponsors. During its investment period, Altaris supported the company as it developed and commercialized a proprietary technology platform to manage patient registries that measure clinical information, provide insight into quality of care and aggregate surgical outcomes.
M2S and Altaris Capital Partners were advised on this transaction by Berkery, Noyes & Co., LLC and Schiff Hardin LLP.
About Altaris Capital Partners, LLC
Altaris Capital Partners, LLC is an investment firm focused exclusively on the healthcare industry. Managing $1.3 billion of equity capital, Altaris invests in businesses that meet clearly defined healthcare needs and leverages its extensive industry knowledge and relationships to accelerate growth and value appreciation. Altaris is based in New York, NY. For more information visit www.altariscap.com.
About M2S, Inc.
M2S provides technology and services to the healthcare industry to manage clinical information, reduce costs, and improve the quality of patient care. Through its PATHWAYS clinical data performance platform, the company supports multiple medical specialty societies and their members by providing comprehensive tools for clinical data management, clinical outcomes assessment and research needs. This secure, cloud-based solution enables physicians, institutions and researchers to collect, manage, analyze and disseminate their clinical data to achieve optimal outcomes. For more information, please visit www.m2s.com.

Franklin, TN Apr 19, 2016 – GAFFEY Healthcare is pleased to announce the appointment of Jennifer LeMieux as Chief Customer Officer.
Ms. LeMieux has almost 20 years of experience in sales and operational roles with the majority focused within healthcare. Having begun her career with companies such as McKinsey & Company, Willis, and HCA she has also demonstrated a clear intent in recent years to work with entrepreneurial, high growth companies.
“This move is certainly a reflection of Jennifer’s talents and leadership within our company,” stated Derek Morkel, GAFFEY CEO. “More importantly, however, it demonstrates a renewed focus on our customers — their experience with our technology; the results that they achieve, and general satisfaction with our technology and services. We have long been known for the strength of our customer relationships and this ensures we do not lose any momentum at a time of significant growth.”

Sioux Falls, SD April 18, 2016 – HealthTronics’ Endocare^® cryotherapy technology was featured on KSFY in Sioux Falls, South Dakota.
Click here to see the report.
Please note: Indications for use of cryotherapy include freezing of the entire prostate gland. Because a warming catheter is used to protect the urethra, the doctor in the KSFY story correctly states that some prostate tissue may remain after treatment.

Dayton, OH Apr 13, 2016 – Home to one of the world’s most advanced pharmaceutical production and development centers and with a large and growing biotech presence, the Caribbean island of Puerto Rico is a globally significant player in the life sciences sector. With its established infrastructure, highly skilled labor force, ready access to the US market and a favorable fiscal climate, the island is a manufacturing or outsourcing base for the majority of the world’s biggest pharma companies. Around 60% of Puerto Rico’s export value is pharma-related and over 25% of the country’s GDP comes from the pharma industry.*
All this pharma activity translates into a sizeable and growing demand for high quality cold chain logistics. Already active in Puerto Rico since 2011, CSafe Global is extending its commitment to this key market with the decision to open a dedicated service and support center adjacent to San Juan’s Luis Munoz Marin International Airport (SJU). The company is the only global provider of a full line of cold chain solutions and the world’s largest producer of actively controlled mobile refrigeration units for life sciences, healthcare, military and international disaster relief agencies. The new service center will provide shippers and logistics providers on the island with a one-stop-shop for a full range of supply, lease, drop-off, maintenance, calibration and technical support services.
According to Brian Kohr, CSafe Global’s CEO, “There are large volumes of high-value pharma-related air cargo coming out of Puerto Rico. Many of these products are sensitive bio-products that must be kept in highly controlled conditions during transit. As the leading US manufacturer of active containers for drug shipments, it will be a big benefit for Puerto Rican shippers to have direct access to a dedicated CSafe Service Centre on the island and allow for access to our full range of cold chain solutions”.
CSafe has established a locally-registered company, CSafe Puerto Rico LLC, and appointed Javier A. Roman as Director of Sales. Javier is a pharma-logistics specialist previously with freight forwarder Kuehne + Nagel. “Javier is a native of Puerto Rico and brings life sciences, logistics and cold chain experience as well as local customer knowledge”, says Brian Kohr. “He is professional, dynamic, and customer focused and will be a strong addition to the CSafe team.”
Mr. Roman explains the importance of having a local presence in Puerto Rico for CSafe. “According to PRIDCO* approximately 25% of the global biologics manufacturing capacity is based in Puerto Rico. This makes it a vital market for CSafe. Puerto Rico has been a thriving and highly competitive base for the production of pharma products for nearly five decades and during this time, a highly efficient network of logistics suppliers has evolved to service local requirements. A direct presence on the island is both expected and necessary in order to provide the exacting levels of service, support and compliance demanded by the pharma majors.”
The new base in Puerto Rico is part of a strategic design by CSafe to expand its presence in key markets. During 2016, the company will open eight new service centers in high growth locations around the world.
*Puerto Rico Industrial Development Company. PRIDCO is a government-owned corporation dedicated to promoting Puerto Rico as an investment destination for companies and industries worldwide.
About Pharma in Puerto Rico

• The pharmaceutical industry represents 26% of the island’s total employment in manufacturing.
• In terms of employment, the sector’s activity generates over 68,000 indirect and induced jobs in the rest of the economy.
• The pharmaceutical industry represents 26.5% of the Island’s Gross Domestic Product.
• Puerto Rico exports in the pharmaceutical industry represents about 57% of all exported commodities.

Source: PIA Pharmaceutical Industry Association of Puerto Rico

Franklin, TN Apr 7, 2016 – MedAssist, a provider of revenue cycle solutions for hospitals, and GAFFEY Healthcare, a provider of automation technology for hospital revenue cycle, today announced a partnership. The partnership enables MedAssist hospital customers a path to improve their net revenue position. MedAssist will begin leveraging the GAFFEY AutoStatus technology to achieve greater efficiency in parts of the claims management process.
“Hospitals often have large volumes of insurance receivables aged 30 days and greater. Yet little information is available regarding why such claims remains unpaid,” said Noel Felipe, Division President for MedAssist. “In helping hospitals collect these accounts, 20-30% of processing time is spent researching why a claim remains unpaid and how to get it paid. By utilizing the GAFFEY AutoStatus technology, our team reduces inefficiencies in that work enabling more focus on value-added efforts such as working denied claims and other activities directly impacting our customers’ net revenue position.”
The GAFFEY Healthcare AutoStatus tool automates the process of retrieving patient claims statuses in a fraction of the time of traditional, manual methods. The technology-driven data management service interfaces with payors to update electronic claims statuses, and can process large amounts of claims often during off-peak hours. The results improve business office work flow by notifying collectors of what claims have been processed, adjudicated or if immediate action or follow-up is needed.
“What ultimately sets GAFFEY apart is that their technology is based on their deep experience leading and operating hospitals,” said Venkat Raman, Chief Executive Officer for MedAssist. “They know what it’s like on the inside and how technology needs to work in a real environment. With GAFFEY we elevate our capabilities, and more importantly, a path for our customers to achieve better financial results and better experiences for their patients.”
“MedAssist is an exciting opportunity,” said Derek Morkel, Chief Executive Officer for GAFFEY Healthcare. “We all want to improve the financial patient experience. That’s tough to achieve without eliminating inefficiencies in the back office revenue cycle work. MedAssist is in the trenches with their hospital customers every day. Now, armed with AutoStatus, they are better positioned to help their customers achieve better results.”

Dayton, OH Mar 28, 2016 – In a continuing commitment to provide timely service, support and container availability to their growing global biopharmaceutical customers, CSafe Global announces the opening of a new service center serving ATL inbound and outbound traffic. This newest location is the second opening of what will be seven new service centers in 2016. Renowned for its quality, innovation and strong customer focus, the company offers a full range of active and passive packaging solutions for the safe transport of temperature-sensitive products.
“CSafe continues to grow with both existing and new customers and we are boosting the number of service centers and facilities around the world to ensure our customers continue to enjoy the best service possible,” says Brian Kohr, President and CEO. “The new facility in Atlanta will strengthen the customer service in this key market. In addition to servicing our existing customer base, the new service center will position us to take advantage of the business growth from the enhanced cargo facilities that are part of the huge capital improvement program now underway at Hartsfield–Jackson.”
The new service center will act as a principle hub for delivery, maintenance, calibration and technical support. The ATL service center will mean that delivery times will be reduced, delivery charges will be minimized, and there will be no ATL drop fees for final destination containers. Mark Mohr, Director of Customer Support and Partner Management at CSafe Global, comments: “This is another welcomed development for the company. Atlanta has a rapidly growing life-science sector, is the world’s busiest airport and is a premier pharma-logistics hub. Our new Atlanta service center will provide a strategic platform for our future growth and play an important role in supporting our expanding client base in this important pharma gateway.”